Ahmann 1976a.
| Study characteristics | ||
| Methods | Accrual dates: not reported Sample size: 68 USA Randomisation method: not reported Baseline comparability: not reported | |
| Participants | Female % first line not reported unclear % metastatic breast cancer (MBC) (72% had visceral dominant disease) Age and ethnicity not stated | |
| Interventions | AC vs CFP vs CAF (+/‐ calusterone)
Arm 1: (AC) doxorubicin + cyclophosphamide
Arm 2: (CFP) cyclophosphamide + 5‐fluorouracil + prednisone
Arm 3: (CAF) cyclophosphamide + doxorubicin + 5‐fluorouracil Ahmann 1976a = AC vs CAF |
|
| Outcomes | Regression (defined as ≥ 50% reduction in tumour mass) Mean response duration Toxicity | |
| Notes | Abstract only available Reports on 68/68 randomised patients Toxicity related death not reported Doses of the same chemotherapy agent are reduced in the addition of a drug arm | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | B ‐ Unclear |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
| Blinding (performance bias and detection bias) All outcomes | Unclear risk | B ‐ Unclear |
| Incomplete outcome data (attrition bias) Response | Low risk | A ‐ Adequate |
| Incomplete outcome data (attrition bias) Toxicity | Low risk | A ‐ Adequate |
| Incomplete outcome data (attrition bias) Time to progression | Low risk | A ‐ Adequate |
| Selective reporting (reporting bias) | Unclear risk | B ‐ Unclear |
| Other bias | Unclear risk | B ‐ Unclear |